In mammals, NAMPT-mediated NAD+ biosynthesis is recognized as a major source of NAD+ 12, and cancer cells rely more severely on NAMPT than healthy cells due to their high NAD+ requirement16, making NAMPT an attractive target for anticancer therapy. The gene discussed is NAMPT; the disease is cancer.